Smaragda Angelidou

Smaragda Angelidou is the Head of CMC of Genespire. She is a CMC subject matter expert with extensive industry experience in cell and gene therapies, from early phase development through to commercialization. She joined Genespire from Autolus, a clinical stage autologous CAR T-cell therapy company, where she was the Senior Director of CMC projects and Tech Transfer. Prior to Autolus, she worked at GlaxoSmithKline, where she held positions in Cell and Gene Therapy Product Development and Medicine and Process Delivery. She was accountable for the strategic, technical, quality and regulatory aspects of CMC development and previously she was a process development technical lead. In her roles, she worked on a number of CGT programs, including autologous TCR T-cell therapies for cancer and ex vivo HSPC gene therapies for rare diseases, which included Strimvelis, the first approved ex vivo autologous gene therapy.

Smaragda holds a BSc in Human Genetics and an MSc in Molecular Medicine from University College, London and a PhD in Molecular Oncology from Imperial College, London.